HIV post-exposure therapy for drug users in treatment

Journal of Substance Abuse Treatment

Volumn 18, Issue 1, 2000, Pages 17-21

  O'Connor, Patrick G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Drug treatment programs; HIV; Prevention; Substance abuse

Indexed keywords

METHADONE;

ARTICLE; CASE REPORT; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; DRUG PROGRAM; ETHICS; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; METHADONE TREATMENT; NEEDLESTICK INJURY; NORMAL HUMAN; NURSE; OCCUPATIONAL EXPOSURE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STAFF;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 0033990873     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(99)00015-X     Document Type: Article

References (12)

1. Carpenter C.C., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association. 277:1997;1962-1969.
2. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. Morbidity and Mortality Weekly Report. 44:1995;929-933.
3. Update. provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV Morbidity and Mortality Weekly Report. 45:1996;468-480.
4. Gostin L.O., Lazzarini Z., Alexander D., Brandt A.M., Mayer K.H., Silverman D.C. HIV testing, counseling, and prophylaxis after sexual assault. Journal of the American Medical Association. 271:1994;1436-1444.
5. Gostin L.O., Lazzarini Z., Jones T.S., Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles. Journal of the American Medical Association. 277:1997;53-62.
6. Jochimsen E.M. Failures of zidovudine prophylaxis. American Journal of Medicine. 102:1997;52-55.
7. Katz M.H., Gerberding J.L. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. New England Journal of Medicine. 336:1997;1097-1100.
8. O'Connor P.G., Molde S., Henry S., Shockor W.T., Schottenfeld R.S. Human immunodeficiency virus infection in intravenous drug users. a model for primary care American Journal of Medicine. 93:1992;382-386.
9. Royce R.A., Sena A., Cates W. Jr., Cohen M.S. Sexual transmission of HIV. New England Journal of Medicine. 336:1997;1072-1078.
10. Schoenbaum E.E., Hartel D., Selwyn P.A., Klein R.S., Davenny K., Rogers M., Feiner C., Friedland G. Risk factors for human immunodeficiency virus infection in intravenous drug users. New England Journal of Medicine. 321:1989;874-879.
11. Sperling R.S., Shapiro D.E., Coombs R.W., Todd J.A., Herman S.A., McSherry G.D., O'Sullivan M.J., Van Dyke R.B., Jimenez E., Rouzioux C., Flynn P.M., Sullivan J.L. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New England Journal of Medicine. 335:1996;1621-1629.
12. Tokars J.I., Marcus R., Culver D.H., Schable C.A., McKibben P.S., Bandea C.I., Bell D.M. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Annals of Internal Medicine. 118:1993;913-919.